Survivin expression in ganglioglioma

Area of Science:

• Neuro-oncology
• Cancer Biology

Background:

• Gangliogliomas are rare central nervous system (CNS) tumors primarily affecting children and young adults, often causing drug-resistant epilepsy.
• While typically well-differentiated with a favorable prognosis, some gangliogliomas can recur or progress to anaplastic, high-grade tumors with a poor outlook.
• Histopathological features alone do not reliably predict clinical outcomes, necessitating the identification of robust prognostic factors.

Purpose of the Study:

• To investigate the expression of survivin, an anti-apoptotic protein, in gangliogliomas.
• To determine if survivin expression correlates with tumor grade, recurrence, or clinical prognosis in gangliogliomas.

Main Methods:

• Immunohistochemistry was used to assess survivin expression in 15 ganglioglioma samples.
• Tumor samples included 10 low-grade and 5 high-grade neoplasms.
• Survivin expression was quantified and correlated with tumor characteristics and clinical history, including recurrence.

Main Results:

• Survivin expression was detected in the neoplastic glial component of 6 out of 15 gangliogliomas.
• Two additional tumors showed survivin expression upon relapse.
• Higher survivin expression (in >5% of neoplastic glial cells) was exclusively observed in malignant and/or recurrent gangliogliomas.

Conclusions:

• Survivin expression in gangliogliomas may serve as a negative prognostic indicator.
• Increased survivin levels might contribute to tumor aggressiveness and malignant progression by promoting cell survival and mutation accumulation.
• Further research is warranted to validate survivin as a prognostic biomarker for gangliogliomas.